Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of <i>Enterobacterales</i> from outpatient centers and nursing homes across the United States (2022–2024)
Ceftibuten is being developed in combination with the oral prodrug of avibactam. Outpatient isolates (<i>n</i> = 500) from 11 US states underwent susceptibility testing with manual broth microdilution. Ceftibuten had susceptibility rates of 64% (CLSI) and 23% (EUCAST). Ceftibuten-avibactam achieved 96.4% inhibition at MIC ≤ 1 µg/mL. Susceptibility rates were as follows: cefpodoxime (2.6%), ceftriaxone (1%), ceftazidime-avibactam (99.6%), tebipenem (89%), ertapenem (94.4%), levofloxacin (26.6%), trimethoprim-sulfamethoxazole (40.2%), and fosfomycin (96.8%). Ceftibuten-avibactam demonstrates potent <i>in vitro</i> activity against cephalosporin non-susceptible isolates.
Authors
- Andrew E. Clark (ORCID: https://orcid.org/0000-0002-0722-0482)
- Kimberly Taylor (ORCID: https://orcid.org/0000-0002-0095-6403)
- Yungchou Wang
- Aliaa Fouad (ORCID: https://orcid.org/0009-0007-6467-1806)
- Monica Srodon
- Lars F. Westblade (ORCID: https://orcid.org/0000-0003-3079-7674)
- Maroun M. Sfeir (ORCID: https://orcid.org/0000-0002-1743-4206)
- Robin R. Chamberland
- A. Brian Mochon
- Isabella W. Martin (ORCID: https://orcid.org/0000-0001-7974-9767)
- Holly Huse (ORCID: https://orcid.org/0009-0004-7586-445X)
- Tomefa E. Asempa (ORCID: https://orcid.org/0000-0002-6268-0924)
- Erik Munson (ORCID: https://orcid.org/0000-0001-5359-6643)
- April M. Bobenchik
- David P. Nicolau (ORCID: https://orcid.org/0000-0002-4148-0165)
Institutions
- Marquette University (US)
- Hartford Hospital (US)
- University of Arizona (US)
- Cornell University (US)
- Quest University Canada (CA)
- Western Connecticut Health Network (US)
- Banner Health (US)
- Regional Health (US)
- UCLouvain Saint-Louis Brussels (BE)
- Harbor–UCLA Medical Center (US)
- Dartmouth Hospital (GB)
- Weill Cornell Medicine (US)
- Dartmouth Health (US)
- UConn Health (US)
- Penn State Milton S. Hershey Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1128/aac.01867-24
- Citations
- 3
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Pfizer